Clinical Trials Logo

Filter by:
NCT ID: NCT06416059 Recruiting - Anxiety Clinical Trials

A Mobile Intervention for Black Individuals Who Engage in Hazardous Drinking

Start date: May 15, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to develop and examine a culturally adapted, mobile health application for the Android and iOS platform. The application uses a personalized feedback intervention (PFI) designed to enhance knowledge regarding adverse anxiety-alcohol interrelations, increase motivation and intention to reduce hazardous drinking, and reduce positive attitudes and intention regarding anxiety-related alcohol use among Black hazardous drinkers with clinical anxiety.

NCT ID: NCT06415461 Recruiting - Pain, Back Clinical Trials

Open Label Dose Ranging Study Assessing the Safety of Cord Blood Product in Sacroiliac Joint Syndrome (SIJ)

SIJ
Start date: May 10, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1 trial. The overall objective is to evaluate the safety and potential efficacy effect of specific type of umbilical cord blood product (CFL001), which, other than specific modifications in manufacturing to render it compatible with cGMP, is essentially similar to that reported in real-world experience.

NCT ID: NCT06415435 Recruiting - Melasma Clinical Trials

Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Microneedling radiofrequency technology has been shown in clinical studies to improve skin quality, tone, pigment, and to treat various skin conditions related to aging. The purpose of this study is to evaluate efficacy and safety of Sylfrim X device for the treatment of melasma.

NCT ID: NCT06415019 Recruiting - Pain Clinical Trials

A Study to Learn About Whether BAY H006689 Causes an Allergic Reaction When Applied as a Topical Gel in Healthy Participants

Start date: June 5, 2024
Phase: Phase 1
Study type: Interventional

Researchers are looking for a better way to treat muscle and joint pain. Researchers have seen that medicines which help reduce pain and inflammation could be safer when applied directly to the skin, called topical application, than when taken by mouth. However, recent studies have found that using these medicines on the skin can sometimes cause skin reactions such as redness, itching, or irritation in the area where the medicine is applied. However, reports of more serious side effects, affecting the entire body, from using these topical medicines are uncommon. The study treatment BAYH006689 is under development to treat muscle and joint pain. In this study, participants will be healthy and will not benefit from BAYH006689. However, the study will provide information on how to test BAYH006689 in future studies in people with muscle and joint pain. The main purpose of this study is to check if BAYH006689 topical gel causes any skin reactions in healthy participants. The skin reactions will be assessed using a scale. This scale will provide scores for redness, swelling, and other signs of skin irritation. In this study, researchers will randomly assign 3 sites, adjacent to each other, on the back of participants' bodies just below the shoulder blades. The following gels will be applied 10 times at these sites as a patch three times a week for 21 days and once after 14-17 days: - BAYH006689 - Placebo, which looks like the study drug but does not have any medicine in it. - 0.9 % saline Each participant will be in the study for around 6 to 8 weeks. During this time they will: - receive assigned treatment gels at the identified skin sites - have their skin reaction symptoms assessed During the study, the doctors and their study team will: - check the medical history of the participants - check participants' health by performing urine tests - ask the participants questions about how they are feeling and what adverse events they are having An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective of whether they think they are related or not to the study treatment.

NCT ID: NCT06414889 Recruiting - Clinical trials for RUNX1 Familial Platelet Disorder

Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

Start date: May 20, 2024
Phase: Early Phase 1
Study type: Interventional

To evaluate the safety and feasibility of collecting hematopoietic stem cells (HSC) in participants with RUNX1-FPD.

NCT ID: NCT06414863 Recruiting - Clinical trials for Palatal Expansion Technique

Effects of Invisalign Palatal Expander System

Start date: May 10, 2024
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the effectiveness of Invisalign Palatal Expander system ingrowing patients. This study compares the treatment outcomes of Invisalign Palatal Expander system to conventional treatments through randomized controlled trial.

NCT ID: NCT06414798 Recruiting - Healthy Volunteers Clinical Trials

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.

Start date: May 13, 2024
Phase: Phase 1
Study type: Interventional

This study will assess the single dose safety, tolerability and pharmacokinetic properties of ABBV-1088 in healthy adult participants

NCT ID: NCT06414317 Recruiting - Clinical trials for Stage IV Bladder Cancer AJCC v8

An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers

Start date: January 12, 2024
Phase: N/A
Study type: Interventional

This clinical trial evaluates the impact of an education and navigation support tool (ENST) on patient and caregiver participation in care coordination for bladder cancer that has spread to nearby tissue or lymph nodes (locally advanced), to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Patients with advanced bladder cancer tend to be older, have multiple medical conditions and often have poor access to health care. An ENST may be an effective method to improve participation in treatment decision-making and care planning among patients with locally advanced, metastatic and unresectable bladder cancer and their caregivers.

NCT ID: NCT06414278 Recruiting - Clinical trials for Malignant Solid Neoplasm

Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy

Start date: February 8, 2024
Phase:
Study type: Observational

This clinical trial evaluates the use of a tool kit, Stress, Affect, Language and Speech Analysis (SALSA), for early identification of cognitive side effects of immunotherapy compared to the standard of care assessment.

NCT ID: NCT06414083 Recruiting - Endometriosis Clinical Trials

Histologic Comparison of Ablative Techniques for Endometriosis

Start date: May 9, 2024
Phase: N/A
Study type: Interventional

To our knowledge, no other human studies directly compare the effectiveness of the various ablative technologies. We set out to design a study to directly compare ablative energy sources and evaluate their ability to destroy native endometriosis tissue in humans.